Announcement.

GLG PHARMA SA (12/2017) Adoption of a resolution regarding the increase of the share capital of GLG Pharma S.A. within the target capital.

The Management Board of GLG Pharma S.A. with its registered office in Wrocław (the "Company") informs that on 5 July 2017 it adopted a resolution regarding the increase of the Company's share capital as part of the authorized capital by issuing F series ordinary bearer shares as part of a private subscription with the exception of the law collection and change of the Company Statute ("Resolution"). According to the resolution, pursuant to art. 444 and following of the Code of Commercial Companies ("Commercial Companies Code") and § 9 of the Company Statute, the Company's share capital is increased within the target capital by an amount no higher than PLN 2,600,000.00, from PLN 15,000.002.00 to no higher than PLN 17,600.002.00 by issuing no more than 1,300,000 ordinary bearer shares of the F series with a nominal value of PLN 2.00 each. The issue price of the Shares is set at PLN 2.25 per share . Shares will be covered by a cash contribution made in full prior to the registration of the share capital increase of the Company. Shares will participate in the dividend in accordance with the following rules: (a) if the Shares are issued in the period from the beginning of the financial year to the dividend date referred to in art. 348 § 2 of the Code of Commercial Companies, the Shares will participate in the profit from the first day of the financial year preceding the year in which they were first issued; (b) if the Shares are issued in the period after the dividend date referred to in art. 348 § 2 of the Code of Commercial Companies, by the end of the financial year, Shares will participate in the profit from the first day of the financial year in which they were issued. Shares will be taken up pursuant to art. 431 § 2 point 1 of the Commercial Companies Code by way of private subscription. The Management Board of the Company will take all actions necessary to implement the Resolution, in particular, it will submit an offer to subscribe for the Shares and conclude agreements regarding the acquisition of the Shares. Share subscription agreements will be concluded not later than on July 31, 2017. The shares will not have the form of a document and will be subject to dematerialization in accordance with the Act of 29 July 2005 on Trading in Financial Instruments. In addition, based on the authorization granted to the Management Board of the Company in § 9 para. 1 and 4 of the Articles of Association of the Company and with the consent of the Company's Supervisory Board, the Management Board of the Company decided to deprive in full the pre-emptive right to series F shares vested in existing shareholdersCompanies. In connection with the increase in the share capital, § 8 para. 1 of the Articles of Association of the Company, the new wording is as follows: "§ 8 1. The share capital of the Company amounts to no more than 17,600.002.00 PLN (seventeen million six hundred thousand two zlotys) and is divided into no more than 8800.001 (eight million eight hundred thousand one) shares with a nominal value of PLN 2.00 (two zloty) each, including: a) 100.001 (one hundred thousand one) ordinary bearer series A shares, b) 800,000 (eight hundred thousand) ordinary bearer series B shares, c) 6,600,000 (six million six hundred thousand) ordinary bearer series E shares, d) no more than 1,300,000 (one million three hundred thousand) series F bearer shares. " The current wording of § 8 paragraph . 1 of the Statutes of the Company: "§ 8. 1. The share capital of the Company amounts to PLN 15,000,002.00 (fifteen million two zlotys) and is divided into 7,500,001 (seven million five hundred thousand one) shares with a par value of PLN 2.00 each, of which: a) 100.001 (one hundred thousand one) series A bearer shares, b) 800,000 (eight hundred thousand) series B bearer shares, c) 6,600,000 (six million six hundred thousand) series E ordinary bearer shares. " The Management Board of the Company also decided that it will apply for the introduction of F series shares to trading in the alternative trading system NewConnect, and therefore intends to dematerialize series F shares in the meaning of the provisions of the Act of 29 July 2005 on trading in financial instruments. Legal basis: § 3 para. 1 point 4) of Appendix No. 3 to the Alternative Trading System Rules "Current and periodic information disclosed in the alternative trading system on the NewConnect market"

Source: company website, investor relations, current and periodic reports.

ALL COMPANY ANNOUNCMENTS
Company information
Company name:GLG Pharma SA
ISIN:PLM100000014
NIP:829 17 32 395
Adress: ul. Duńska 9 54-427 Wrocław
Phone:+48 71 758 09
website:www.glgpharma.pl

Copyright © 2017 PolandStockExchange
This website uses cookies (Regulations / Cookie Policy).